Beryl Drugs

  • Market Cap: Micro Cap
  • Industry: Pharmaceuticals & Biotechnology
  • ISIN: INE415H01017
  • NSEID:
  • BSEID: 524606
INR
24.70
0.27 (1.11%)
BSENSE

Nov 20

BSE+NSE Vol: 4.13 k

  • Price Points
  • Score
  • Mojo Parameters
  • Total Return
  • News and Corporate Actions
  • Key factors
  • Shareholding
  • Financials
  • CompanyCV
{
  "main_header": {
    "sid": 302214,
    "name": "Beryl Drugs",
    "stock_name": "Beryl Drugs",
    "full_name": "Beryl Drugs Ltd",
    "name_url": "stocks-analysis/beryl-drugs",
    "exchange": 0,
    "exchangecode": "",
    "country_id": 34,
    "currency": "INR",
    "cmp": "24.70",
    "chg": 0.27,
    "chgp": "1.11%",
    "dir": 1,
    "prev_price": "24.43",
    "mcapval": "12.00 Cr",
    "mcap": "Micro Cap",
    "scripcode": 524606,
    "symbol": "",
    "ind_name": "Pharmaceuticals & Biotechnology",
    "ind_code": 4,
    "indexname": "",
    "isin": "INE415H01017",
    "curr_date": "Nov 20",
    "curr_time": "",
    "bse_nse_vol": "4.13 k",
    "exc_status": "Active",
    "traded_date": "Nov 20, 2026",
    "traded_date_str": "2026 11 20",
    "score": "",
    "scoreText": "",
    "Live": 0,
    "market_time": 0,
    "is_blur": 1,
    "is_blur_class": "blur-registerF-score-header",
    "is_blur_url": "https://researchintel.adityabirlamoney.com/ABML-Landingstocks-analysis/beryl-drugs-302214-0&utm_source=Spage_Header_Score",
    "mojoone": {
      "ismore": 0
    }
  },
  "news": {
    "results": [
      {
        "title": "Beryl Drugs Ltd Upgraded to Hold by MarketsMOJO on Improving Technicals and Valuation",
        "link": "https://researchintel.adityabirlamoney.com/news/stock-recommendation/beryl-drugs-ltd-upgraded-to-hold-by-marketsmojo-on-improving-technicals-and-valuation-4263197",
        "imagepath": "https://i.marketsmojo.com/newsimg/2026/11/BerylDrugsLtd_mojoScore_4263197.png",
        "date": "2026-11-16 08:08:56",
        "description": "Beryl Drugs Ltd, a micro-cap player in the Pharmaceuticals & Biotechnology sector, has seen its investment rating upgraded from Sell to Hold as of 13 Nov 2026. This change reflects a nuanced improvement across technical indicators, valuation metrics, financial trends, and overall quality assessments, signalling a cautious but positive outlook for investors."
      },
      {
        "title": "Beryl Drugs Gains 3.70%: 2 Key Factors Driving the Week’s Momentum",
        "link": "https://researchintel.adityabirlamoney.com/news/stocks-in-action/beryl-drugs-gains-370-2-key-factors-driving-the-weeks-momentum-4237931",
        "imagepath": "",
        "date": "2026-10-25 11:00:32",
        "description": "    <div class=\"article-news-new\">\n        <div class=\"article-container\">\n\n<div class=\"article-content\">\n                <div class=\"highlight-box\">\n                    <h3>Key Events This Week</h3>\n                    <p><strong>19 Oct:</strong> Upgrade to Hold rating by MarketsMOJO citing improved technicals and valuation</p>\n                    <p><strong>21 Oct:</strong> New 52-week high reached at Rs.27.9</p>\n                    <p><strong>23 Oct:</strong> Week closes at Rs.24.69, up 3.70% vs Sensex down 3.75%</p>\n                </div>\n\n                <div class=\"stats-row\">\n                    <div class=\"stat-item\">\n                        <div class=\"stat-label\">Week Open</div>\n                        <div class=\"stat-value\">Rs.23.81</div>\n                    </div>\n                    <div class=\"stat-item\">\n                        <div class=\"stat-label\">Week Close</div>\n                       ..."
      },
      {
        "title": "Beryl Drugs Ltd Upgraded to Hold as Technicals Improve and Valuation Attractiveness Increases",
        "link": "https://researchintel.adityabirlamoney.com/news/stock-recommendation/beryl-drugs-ltd-upgraded-to-hold-as-technicals-improve-and-valuation-attractiveness-increases-4230621",
        "imagepath": "https://i.marketsmojo.com/newsimg/2026/10/BerylDrugsLtd_mojoScore_4230621.png",
        "date": "2026-10-20 08:16:44",
        "description": "Beryl Drugs Ltd, a micro-cap player in the Pharmaceuticals & Biotechnology sector, has seen its investment rating upgraded from Sell to Hold as of 19 Oct 2026. This change reflects a notable improvement in the company’s technical indicators and valuation metrics, despite flat recent financial performance. The upgrade is underpinned by a more bullish technical trend, attractive valuation ratios, and a stable financial trend, positioning the stock for cautious optimism amid a challenging market backdrop."
      },
      {
        "title": "Beryl Drugs Ltd Downgraded to Sell Amid Mixed Financial and Technical Signals",
        "link": "https://researchintel.adityabirlamoney.com/news/stock-recommendation/beryl-drugs-ltd-downgraded-to-sell-amid-mixed-financial-and-technical-signals-4224972",
        "imagepath": "https://i.marketsmojo.com/newsimg/2026/10/BerylDrugsLtd_mojoScore_4224972.png",
        "date": "2026-10-14 08:09:58",
        "description": "Beryl Drugs Ltd, a micro-cap player in the Pharmaceuticals & Biotechnology sector, has seen its investment rating downgraded from Hold to Sell as of 13 Oct 2026. This shift reflects a complex interplay of technical indicators, valuation metrics, financial trends, and overall quality assessments, signalling caution for investors despite some pockets of resilience in recent performance."
      },
      {
        "title": "Beryl Drugs Ltd Upgraded to Hold as Technicals Improve and Valuation Attracts Investors",
        "link": "https://researchintel.adityabirlamoney.com/news/stock-recommendation/beryl-drugs-ltd-upgraded-to-hold-as-technicals-improve-and-valuation-attracts-investors-4223734",
        "imagepath": "https://i.marketsmojo.com/newsimg/2026/10/BerylDrugsLtd_mojoScore_4223734.png",
        "date": "2026-10-13 08:20:51",
        "description": "Beryl Drugs Ltd, a micro-cap player in the Pharmaceuticals & Biotechnology sector, has seen its investment rating upgraded from Sell to Hold as of 12 Oct 2026. This revision reflects a nuanced improvement across multiple parameters including technical indicators, valuation metrics, and financial trends, despite some lingering concerns over long-term fundamentals. The company’s recent performance and market positioning warrant a closer examination for investors seeking clarity on its prospects."
      },
      {
        "title": "Beryl Drugs Ltd Upgraded to Hold as Technicals and Valuation Improve",
        "link": "https://researchintel.adityabirlamoney.com/news/stock-recommendation/beryl-drugs-ltd-upgraded-to-hold-as-technicals-and-valuation-improve-4210553",
        "imagepath": "https://i.marketsmojo.com/newsimg/2026/10/BerylDrugsLtd_mojoScore_4210553.png",
        "date": "2026-10-01 08:08:16",
        "description": "Beryl Drugs Ltd, a micro-cap player in the Pharmaceuticals & Biotechnology sector, has seen its investment rating upgraded from Sell to Hold as of 30 September 2026. This change reflects notable improvements in the company’s technical indicators and valuation metrics, despite flat recent financial performance. The upgrade highlights a cautiously optimistic outlook amid mixed fundamental signals and a strong market-beating return over the past year."
      },
      {
        "title": "Beryl Drugs Ltd Downgraded to Sell Amid Mixed Financial and Technical Signals",
        "link": "https://researchintel.adityabirlamoney.com/news/stock-recommendation/beryl-drugs-ltd-downgraded-to-sell-amid-mixed-financial-and-technical-signals-4207776",
        "imagepath": "https://i.marketsmojo.com/newsimg/2026/9/BerylDrugsLtd_mojoScore_4207776.png",
        "date": "2026-09-29 08:09:10",
        "description": "Beryl Drugs Ltd, a micro-cap player in the Pharmaceuticals & Biotechnology sector, has seen its investment rating downgraded from Hold to Sell as of 28 Sep 2026. This change reflects a nuanced assessment across four key parameters: quality, valuation, financial trend, and technicals. Despite some positive technical signals and attractive valuation metrics, the company’s weak long-term fundamentals and flat recent financial performance have weighed heavily on the overall outlook."
      },
      {
        "title": "Beryl Drugs Ltd Upgraded to Hold as Technicals Improve and Valuation Attractiveness Increases",
        "link": "https://researchintel.adityabirlamoney.com/news/stock-recommendation/beryl-drugs-ltd-upgraded-to-hold-as-technicals-improve-and-valuation-attractiveness-increases-4175386",
        "imagepath": "https://i.marketsmojo.com/newsimg/2026/8/BerylDrugsLtd_mojoScore_4175386.png",
        "date": "2026-08-31 08:02:06",
        "description": "Beryl Drugs Ltd, a micro-cap player in the Pharmaceuticals & Biotechnology sector, has seen its investment rating upgraded from Sell to Hold as of 28 August 2026. This change reflects a nuanced improvement across technical indicators, valuation metrics, and financial trends, despite ongoing challenges in long-term fundamentals and market performance."
      }
    ],
    "total": 20,
    "sid": "302214",
    "stock_news_url": "https://researchintel.adityabirlamoney.com/news/beryl-drugs-302214"
  },
  "announcements": [
    {
      "caption": "Announcement under Regulation 30 (LODR)-Newspaper Publication",
      "datetime": "16-Nov-2026",
      "details": "NEWSPAPER PUBLICATION",
      "source": "BSE"
    },
    {
      "caption": "UNAUDITED FINANCIAL RESULTS FOR THE QUARTER ENDED 30.09.2026",
      "datetime": "14-Nov-2026",
      "details": "UNAUDITED FINANCIAL RESULTS FOR THE QUARTER ENDED 30.09.2026",
      "source": "BSE"
    },
    {
      "caption": "Board Meeting Outcome for OUTCOME OF BOARD MEETING",
      "datetime": "14-Nov-2026",
      "details": "OUTCOME OF BOARD MEETING",
      "source": "BSE"
    }
  ],
  "corporate_actions": [
    {
      "img": "board-meeting.svg",
      "title": "BOARD MEETING",
      "msg": "<span>No</span> Upcoming Board Meetings",
      "data": []
    },
    {
      "img": "dividend.svg",
      "title": "DIVIDEND",
      "msg": "No <strong>Dividend</strong> history available",
      "data": []
    },
    {
      "img": "splits.svg",
      "title": "SPLITS",
      "msg": "No <strong>Splits</strong> history available",
      "data": []
    },
    {
      "img": "bonus.svg",
      "title": "BONUS",
      "msg": "No <strong>Bonus</strong> history available",
      "data": []
    },
    {
      "img": "rights-issues.svg",
      "title": "RIGHTS",
      "msg": "No <strong>Rights</strong> history available",
      "data": []
    }
  ]
}
stock newsNews and Views
stock-recommendationAnnouncement

Announcement under Regulation 30 (LODR)-Newspaper Publication

16-Nov-2026 | Source : BSE

NEWSPAPER PUBLICATION

UNAUDITED FINANCIAL RESULTS FOR THE QUARTER ENDED 30.09.2026

14-Nov-2026 | Source : BSE

UNAUDITED FINANCIAL RESULTS FOR THE QUARTER ENDED 30.09.2026

Board Meeting Outcome for OUTCOME OF BOARD MEETING

14-Nov-2026 | Source : BSE

OUTCOME OF BOARD MEETING

stock-recommendationCorporate Actions
Corporate Actions
info
stock-summary
BOARD MEETING

No Upcoming Board Meetings

stock-summary
DIVIDEND

No Dividend history available

stock-summary
SPLITS

No Splits history available

stock-summary
BONUS

No Bonus history available

stock-summary
RIGHTS

No Rights history available